Search

Displaying results 1341 - 1350 of 4004 in total
  1. Drug

    Temazepam

    go.drugbank.com/drugs/DB00231
    Approved

    synthesis of temazepam was established by 1965 [A175333], mainstream contemporary use of the medication did not occur until it's legitimate use as treatment for insomnia was accepted and approved later on

  2. Drug

    Tolterodine

    go.drugbank.com/drugs/DB01036
    ApprovedInvestigational

    Tolterodine acts on M2 and M3 subtypes of muscarinic receptors.

  3. Drug

    Delandistrogene moxeparvovec

    go.drugbank.com/drugs/DB16802
    ApprovedInvestigational

    It was granted accelerated approval by the FDA on June 22, 2023, as the first gene therapy to treat Duchenne Muscular Dystrophy (DMD). … [A260261] Delandistrogene moxeparvovec comprises a non-replicating, recombinant adeno-associated virus serotype rh74 (AAVrh74) based vector containing the microdystrophin transgene under the control

  4. Drug

    Pegfilgrastim

    go.drugbank.com/drugs/DB00019
    ApprovedInvestigational

    [A187601] The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti-cancer … [L9974] NIOPEG (pegfilgrastim), a biosimilar of NEULASTA®, was approved by Health Canada in April 2024 for the prevention of febrile neutropenia in patients with non-myeloid malignancies receiving myelosuppressive

  5. Drug

    Ranolazine

    go.drugbank.com/drugs/DB00243
    ApprovedInvestigational

    Chronic angina is a common cardiovascular condition affecting millions worldwide and causes significant disability while interfering with daily activities. Ranolazine is a well-tolerated piperazine derivative used for the management of t...

  6. Drug

    Letermovir

    go.drugbank.com/drugs/DB12070
    ApprovedInvestigational

    Letermovir recieved approval from the FDA on November 8th, 2017 for use in prophylaxis of cytomegalovirus (CMV) infection in allogeneic hematopoietic stem cell transplant patients.

  7. Drug

    Ganirelix

    go.drugbank.com/drugs/DB06785
    ApprovedInvestigational

    [A252195] Ganirelix was first approved by the FDA on July 29, 1999.[L43070]

  8. Drug

    Ombitasvir

    go.drugbank.com/drugs/DB09296
    ApprovedInvestigational

    Ombutasvir first came on the market as a fixed-dose combination product with [DB09183], [DB09297], and [DB00503] as the FDA-approved product Viekira Pak. … Depending on the genotype, Ombitasvir is often used in combination with other antivirals such as [DB09183], [DB09297], [DB00503], and [DB00811] with the intent to cure, or achieve a sustained virologic

  9. Drug

    Amylocaine

    go.drugbank.com/drugs/DB09088
    ApprovedWithdrawn

    Despite the introduction of using cocaine injections for regional anesthesia in 1884, non-addictive substitutes were sought after immediately [L1882]. … Finally, in 1903 the world's first synthetic and non-addictive local anesthetic, amylocaine, was synthesized and patented under the name Forneaucaine by Ernest Fourneau at the Pasteur Institute [L1882]

  10. Drug

    Lisocabtagene maraleucel

    go.drugbank.com/drugs/DB16582
    ApprovedInvestigational

    [A228493] However, data on the efficacy of CAR T-cell therapies on less severe forms of B-cell lymphoma are lacking. … [A228493] Lisocabtagene maraleucel was granted FDA approval on 5 February 2021 [L31583] and EC approval on 5 April 2022.[L42210] It was later granted Health Canada approval on 6 May 2022.